Endovia Health Sciences vs LQR House
LQR House is the larger business, with $1.6m of revenue in fiscal 2025 against $73,066 for Endovia Health Sciences (21.4 times as much). LQR House grew faster (-37.4% against -90.9%). LQR House kept more of each dollar of sales as profit: a net margin of -1631.0% against -34537.0%.
| Latest fiscal year | Endovia Health SciencesEDVA, 2025 | LQR HouseYHC, 2025 |
|---|---|---|
| Revenue | $73,066 | $1.6m |
| Revenue growth | -90.9% | -37.4% |
| Net income | −$25.2m | −$25.5m |
| Operating margin | — | -730.3% |
| Net margin | -34537.0% | -1631.0% |
| Return on equity | — | -177.2% |
| Free cash flow | −$4.8m | −$34.2m |
| Cash | $281,435 | $6.0m |
| Total debt | $6.2m | $7.2m |
| Debt to equity | — | 24.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $134,451 | $529,724 |
| Price vs our value range | — | — |
| Moat score | 25 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 0 sales |